| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-08-26 |
| タイトル |
|
|
タイトル |
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Mesothelioma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Chemotherapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Pemetrexed |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Platinum |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Second-line |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Ono, Sawana
Taniguchi, Hirokazu
Kuroda, Koji
Hashimoto, Teppei
Okada, Asuka
Goto, Yasuhiro
Kitai, Hidenori
Nakamura, Yoichi
Ogusu, Shinsuke
Hase, Tetsunari
Ota, Takayo
Ebi, Noriyuki
Furugen, Makoto
Harada, Taishi
Kinoshita, Yoshiaki
Mizoguchi, Takaki
Nakatomi, Katsumi
Soejima, Yoshifumi
Yamada, Takahiro
Takemoto, Shinnosuke
Mukae, Hiroshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
There is limited evidence regarding the second-line treatment for patients with unresectable, advanced, or metastatic pleural mesothelioma receiving first-line nivolumab plus ipilimumab combination immunotherapy. Although chemotherapy with pemetrexed and a platinum-based agent is empirically administered as the second-line treatment in clinical practice, its effect in patients after nivolumab plus ipilimumab remains unclear. Therefore, this retrospective observational study aimed to elucidate the efficacy of pemetrexed plus platinum therapy as a second-line treatment for pleural mesothelioma after first-line nivolumab-ipilimumab immunotherapy. Forty-three patients with unresectable or advanced pleural mesothelioma were enrolled in this study. Median overall survival was 17.1 months (95 % confidence interval [CI]: 9.3- not estimable), and median progression-free survival was 5.7 months (95 % CI: 3.9–11.9). The one-year overall survival rate was 62.8 % (95 % CI: 45.0–76.3) and one-year progression-free survival rate was 26.2 % (95 % CI: 10.4–45.2). In patients with measurable lesions, the overall response rate was 30.3 % and disease control rate was 69.7 %. These results are similar to those of previous studies on pemetrexed-platinum for pleural mesothelioma in first-line settings, suggesting that pemetrexed-platinum therapy can be considered an appropriate choice for the second-line treatment of mesothelioma after immunotherapy. |
|
言語 |
en |
| 書誌情報 |
en : Lung Cancer
巻 207,
p. art. no. 108709,
発行日 2025-08-16
|
| 出版者 |
|
|
出版者 |
Elsevier B.V. |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
01695002 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.lungcan.2025.108709 |
| 権利 |
|
|
権利情報 |
© 2025 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Lung Cancer, 207, art. no. 108709; 2025 |
|
言語 |
en |
LC207_108709.pdf (918 KB)
